The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: The influence on arrhythmia, heart rate variability and repolarization parameters

Lupus

Volumn 15, Issue 8, 2006, Pages 521-525

  Wozniacka, Anna ^a   Cygankiewicz, I ^a   Chudzik, M ^a   Sysa Jedrzejowska A ^a   Wranicz, J K ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Arrhythmias; Cardiac toxicity; Chloroquine treatment; Heart rate variability; Holter monitoring; Repolarization; Systemic lupus erythematosus

Indexed keywords

CHLOROQUINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART RATE VARIABILITY; HEART REPOLARIZATION; HOLTER MONITORING; HUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; ARRHYTHMIA; ARRHYTHMIAS, CARDIAC; CHLOROQUINE; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART RATE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE POTENTIALS; MIDDLE AGED;

EID: 33747888289     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203306lu2345oa     Document Type: Article

References (33)

1. Ritschel WA, Hammer GV, Thompson GA. Pharmakinetics of antimalarials and proposals for dosage regiments. Int J Clin Pharmacol Biopharm 1978; 16: 395-401.
2. Laaksonem AL, Koskiahde V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. Scad J Rheumatol 1974; 3: 103-108.
3. McChesney EW, Rothfield NF. Comparative metabolic studies of chloroquine and hydroxychloroquine. Arthritis Rheum 1964; 7: 328-329.
4. Wallace DJ. Antimalarials: the real advance in lupus. Lupus 2001; 10: 385-387.
5. Baguet JP, Tremel F, Fahre M. Chloroquine cardiomyopathy with conduction disorders. Heart 1999; 81: 221-223.
6. Cervera. Cardiac toxicity secondary to long term treatment with chloroquine. Am Rheum Dis 2001; 60: 301-302.
7. Teixeira RA, Martinelli Filho M, Benvenuti LA et al. Cardiac damage from chronic use of chloroquine: a case report and review of the literature. Arq Bras Cardiol 2002; 79: 85-88.
8. Nord JE, Shah PK, Rinaldi RZ, Weisman MH. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum 2004; 33: 336-351.
9. McAllister HA Jr, Ferrans VJ, Hall RJ, Strickman NE, Bossart MI. Chloroquine-induced cardiomyopathy. Arch Pathol Lab Med 1987; 111: 953-956.
10. Veinot JP, Ma KT, Zarychanski R. Chloroquine related toxicity. J Rheumatol 1998; 25: 1221-1225.
11. Freihage JH, Patel NC, Jacobs WR et al. Heart transplantation in patient with chloroquine-induced cardiomyopathy. J Heart Lung Transplant 2004; 23: 252-255.
12. Naqvi TZ, Luthringer D, Marchevsky A, Saouf R, Gul K, Buchbinder NA. Chloroquine-induced cardiomyopathy-echocardiographic features. J Am Soc Echocardiogr 2005; 18: 383-387.
13. Kang J, Chen XL, Wang L, Rampe D. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. J Pharmacol Exp Ther 2001; 299: 290-296.
14. Heart rate variability. Standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996; 93: 1043-1065.
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
16. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
17. D'Cruz D, Khamashta M, Hughes G. Cardiovascular manifestations of systemic lupus erythematosus. In Wallace DJ, Hahn BH eds. Systemic lupus erythematosus. Lippincott Williams & Wilkins, 2002: 661-645.
18. Landewe RB, Miltenburg AM, Breedveld FC et al. Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis. J Rheumatol 1992; 19: 1353-1357.
19. Salmeron G, Lipsky PE. Immunosupressive potential of antimalarials. Am J Med 1983; 18: 19-24.
20. Sjolin-Forsberg G, Berne B, Eggelte TA et al. In situ localization of chloroquine and immunohistological studies in UVB-irradiated skin of photosensitive patients. Acta Derm Venereol 1995; 22: 221-225.
21. Olczyk K, Drozdz M, Kucharz E et al. Studies on the activity of selected lysosomal exoglycosidases in patients with systemic lupus erythematosus. Med Interne 1984; 22: 221-225.
22. Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 1996; 5: S4-S10.
23. Sperber K, Quraishi H, Kalb TH et al. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1) and IL-6 in humans monocytes and T cells. J Rheumatol 1993; 20: 803-808.
24. Yi AK, Peckham DW, Ashman RF, Krieg A. CpG DNA rescues B cells from apoptosis by activating NFkB and preventing mitochondrial membrane potential disruption via chloroquine-sensitive pathway. Int Immunol 1999; 11: 2015-2024.
25. Coban C, Ishii KJ, Kawai T et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. JEM 2005; 201: 19-25.
26. Lenert P. Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol 2005; 140: 1-10.
27. Sjolin-Frsberg G, Berne B, Blixt C et al. Chloroquine phosphate: a long term follow up of drug concentration in skin suction blister fluid and plasma. Acta Derm Venereol 1993; 73: 426-429.
28. Reuss-Borst M, Berner B, Wulf G, Muller GA. Complete heart block as a rare complication of treatment with chloroquine. J Rheumatol 1999; 26: 1394-1395.
29. Comin-Colet J, Sanchez-Corral MA, Alegre-Sancho JJ et al. Complete Heart block in an adult with systemic lupus erythematosus and recent onset of hydroxychloroquine therapy. Lupus 2001; 10: 59-62.
30. Guedira N, Hajjaj-Hassouni N, Srairi JE, el Hassani S, Fellat R, Benomar M. Third-degree atrioventricular block in a patient under chloroquine theraphy. Rev Rhum Engl Ed 1998; 65: 58-62.
31. Harris L, Downar E, Shaikh NA, Chen T. Antiarrhythmic potential of chloroquine: new use for an old drug. Can J Cardiol 1988; 4: 295-300.
32. Touze JE, Heno L, Foucade JC et al. The effect of antimalarial drugs on ventricular repolarization Am J Trop Med Hyg 2002; 67: 54-60.
33. Looareesuwan S, White NJ, Chanthavanich P et al. Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. Br J Clin Pharmacol 1986; 22: 31-36.